Dr. Danit Ariel, MD

Dr. Ariel practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Ariel's NPI, 1528248267, was assigned on November 9, 2007. Dr. Ariel graduated from UC Davis School of Medicine in 2007. Dr. Ariel holds California license A105110.

Dr. Ariel's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Ariel's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Ariel to 1 more hospital, named with a free account. Dr. Ariel's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ariel practices, 2 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Ariel's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Ariel is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dr. Ariel is licensed in California.

Dmand AI lists chronic diabetes, enlarged thyroid, osteoporosis, overactive thyroid, testicular dysfunction and underactive thyroid among the conditions Dr. Ariel treats.

CMS data shows 15 Medicare services from Dr. Ariel across 1 procedure code in 2024, all of them office visits, for 31 Medicare patients. Medicare paid $2,411 for them. Every service was in an office.

CMS counts 31 Medicare patients who saw Dr. Ariel in 2024. The largest group is 65 to 74, with 11 patients. 71% of them have high blood pressure, and 55% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ariel's median patient age at 45, with 67% women.

In 2024, Dr. Ariel wrote 60 Medicare Part D claims for 13 patients. 75% of them were for generic drugs. CMS names the drug for 30 of them, across 2 drugs with 11 or more claims each, at $508 in total drug cost. In 2023, CMS named 56 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Ariel for performance year 2024, reported as part of a group. Dr. Ariel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ariel as offering telehealth.

Dmand AI links 27 papers to Dr. Ariel, published from 2012 to 2025. 2015 was the busiest year, with 6. The most frequent topics are Blood Glucose, Insulin Resistance and Obesity. Dr. Ariel has published most often in Curr Opin Obstet Gynecol. Dr. Ariel's most frequent co-authors are Alice Liu, MD, Fahim Ahmad Abbasi, MD and Sun Hee Kim, MD, MS.

CMS Open Payments shows 2 general payments to Dr. Ariel from 2 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Astellas Pharma US Inc paid the most, $127.

Dr. Ariel graduated from UC Davis School of Medicine in 2007. Dr. Ariel is a member of AACE and North American Menopause Society.

Dr. Ariel is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.